Overview

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Doxorubicin
Estramustine
Etoposide
Etoposide phosphate
Ketoconazole
Liposomal doxorubicin
Paclitaxel
Vinblastine